UnknownPhase 3

Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial

200 participantsStarted 2021-04-10

Plain-language summary

This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women age 18 or older * Hospitalized and requiring medical care for COVID-19 * Presenting respiratory failure cause by COVID 19 requiring oxygen and/or mechanical ventilation support * With radiographic evidence of pulmonary infiltrate * Able to give informed consent or, if unable to do so regarding the medical condition, having relatives able of consenting for the patient Exclusion Criteria: * Pregnancy * Patients with pre-existing terminal condition with life expectancy \< 6 months * Patients with pre-existing severe lung disease requiring home O2 * History of seizure disorder * History of adverse reaction to antihistamines or to Cyproheptadine

What they're measuring

Length of hospitalization

Timeframe: Through study completion, an average of 1 year

Need mechanical ventilation (Non invasive or Invasive)

Timeframe: Through study completion, an average of 1 year

Trial details

NCT IDNCT04820751

SponsorCiusss de L'Est de l'Île de Montréal

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-11-01

Contact for this trial

Philippe Rola, MD

514 252-6000 philippe.rola@gmail.com

View on ClinicalTrials.gov More Viral Pneumonia trials